top of page

Redalpine invests in aktiia, the future of blood pressure monitoring


aktiia has raised a CHF 4 million Seed Round


We are happy to announce our next Redalpine Capital III healthtech investment, aktiia. The Neuchatel, Switzerland-based startup is reinventing blood pressure monitoring. As a major milestone  the company has now raised a CHF 4 million seed round led by Redalpine and Silicon Valley based TransLink Capital. The funding will be used to further develop and validate its algorithms and product offerings as well as establish strategic third-party partnerships.


aktiia’s patented technology combines common optical sensors, widely-known for tracking heart-rate in today’s wearables, and clinically validated software algorithms to measure an individual’s blood pressure continuously and cufflessly at the wrist. The algorithms will be embedded in non-medical third-party wearables for preventive purposes to track blood pressure trends, as well as in aktiia’s medical grade wearable to monitor precise blood pressure values that can be used for the diagnosis and management of hypertension.  


Mattia Bertschi, aktiia co-founder and CEO stated: “There’s an urgent need to address the problem of hypertension, as it affects every third adult, and is the largest epidemic known to mankind. We will empower people with cutting edge technology in this fight.”


Our partner Michael Sidler added: “This technology is a quantum leap in the fight against hypertension and will revolutionize the way we look at blood pressure.”


We are excited  to support Mattia and the aktiia team to bring this groundbreaking technology to market!  

Comments


bottom of page